BioMed Partners has invested in TRiCares’ EUR22 million Series B financing round.
TRiCares is developing a transcatheter-based tricuspid valve replacement system aimed at addressing the need for a better treatment for this frequent and severe disease that avoids open heart surgery. Heart valve diseases are among the most serious cardiac complications affecting more than 12.7 million patients in Europe.
In the last decade minimally invasive catheter-based solutions have been developed for other valve diseases but for patients with tricuspid valve disease open-heart surgeries remain the standard treatment. Owing to high mortality, access to such surgery is severely restricted leaving surgeons seeking for alternative minimally-invasive approach, low-risk solutions to treat many patients.
Thomas Möller, General Partner BioMedPartners will represent BioMed will on the board.
